Strong expansion of normal CD19‐negative B‐cell precursors after the use of blinatumomab in the first‐line therapy of acute lymphoblastic leukaemia in children

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2022-01, Vol.196 (1), p.e6-e9
Hauptverfasser:	Mikhailova, Ekaterina, Roumiantseva, Julia, Illarionova, Olga, Lagoyko, Svetlana, Miakova, Natalia, Zerkalenkova, Elena, Zharikova, Liudmila, Olshanskaya, Yulia, Novichkova, Galina, Maschan, Michael, Henze, Guenter, Karachunskiy, Alexander, Popov, Alexander
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute lymphoblastic leukemia ALL Antibodies, Bispecific - administration & dosage Antibodies, Bispecific - adverse effects Antibodies, Bispecific - therapeutic use Antigens, CD19 - metabolism Antineoplastic Agents, Immunological - therapeutic use CD19 antigen CD19 targeting CD19‐negative precursors Child Child, Preschool Clonal Evolution flow cytometry Humans minimal residual disease Molecular Targeted Therapy Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - etiology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy Precursor Cells, B-Lymphoid - metabolism Precursor Cells, B-Lymphoid - pathology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!